EVH Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Evolent Health Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 27.65 USD -2.37%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast EVH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EVH is 45.56 USD with a low forecast of 34.34 USD and a high forecast of 66.15 USD.

EVH Lowest Forecast

Wall Street Target

EVH Average Forecast

Wall Street Target

EVH Highest Forecast

Wall Street Target

24% Upside

65% Upside

139% Upside

The latest public price target was made on Apr 17, 2024 by Jessica Tassan from Piper Sandler , who expects EVH stock to rise by 84% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Jessica Tassan Piper Sandler	51 USD Upside 84%	1 week ago Apr 17, 2024	Piper Sandler Reiterates Overweight Rating on Evolent Health (EVH) StreetInsider
Richard Close Canaccord Genuity	44 USD Upside 59%	1 month ago Mar 28, 2024	Evolent Health (EVH) PT Lowered to $44 at Canaccord Genuity StreetInsider

Price Target	51 USD
Upside/Downside	84%

Price Target	44 USD
Upside/Downside	59%

Sophia Genetics SA

76% Upside

Augmedix Inc

117% Upside

Mentice AB

65% Downside

Pharmagest Interactive SA

52% Upside

Sophia Genetics SA

76% Upside

Augmedix Inc

117% Upside

Mentice AB

65% Downside

Pharmagest Interactive SA

52% Upside

ContextVision AB

28% Upside

Renalytix PLC

484% Upside

Inspire Medical Systems Inc

9% Upside

Carasent ASA

82% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Evolent Health Inc's revenue is 46%. The projected CAGR for the next 3 years is 19%.

46%

19%

-1%

What are analyst estimates?

Operating Income
Forecast

The compound annual growth rate of Evolent Health Inc's operating income for the next 3 years is 180%.

N/A

180%

N/A

What are analyst estimates?

Net Income
Forecast

N/A

N/A

N/A

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for EVH is 45.56 USD with a low forecast of 34.34 USD and a high forecast of 66.15 USD.

For the last 8 years the compound annual growth rate for Evolent Health Inc's revenue is 46%. The projected CAGR for the next 3 years is 19%.

The compound annual growth rate of Evolent Health Inc's operating income for the next 3 years is 180%.

Join more than 132,300+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.